Physician profile
Shailesh Asaikar
NPI 1770695181
$25,992.84
in general payments reported to CMS, 2019-2025
51 companies · $3,680 in 2025
The $3,680 reported for 2025 was more than what 84% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,822 · 2020: $5,448 · 2021: $2,799 · 2022: $2,908 · 2023: $2,157 · 2024: $3,178 · 2025: $3,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,015.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $3,975.18 | 2019-2021 | |
| Tris Pharma INC | $3,187.92 | 2019-2025 | Dyanavel Xr, Quillivant |
| Ucb, INC. | $3,151.59 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Ucb Sa | $2,160.00 | 2020 | |
| Neurelis, INC. | $1,812.68 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $1,343.36 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $973.08 | 2019-2025 | Qelbree |
| Livanova USA, INC. | $888.23 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $845.66 | 2022-2025 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $727.02 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $567.21 | 2023-2025 | Fycompa |
| Eisai INC. | $558.03 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $505.31 | 2020-2023 | Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $370.17 | 2019-2020 | |
| Genentech USA, INC. | $347.22 | 2020-2025 | Evrysdi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Asaikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.